Testing BAT5906 vs Lucentis for diabetic vision swelling
Treatments studied
Part of Eyes & vision clinical trials.
This study compares two injectable medicines (BAT5906 and Lucentis) to treat diabetic macular edema—swelling in the back of the eye that blurs vision. Both drugs block a protein that causes abnormal blood vessel leakage, and this trial will show which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes and are 18–80 years old
- You have diabetic macular edema (swelling in the center of the retina) confirmed by eye imaging
- Your vision in the affected eye is between 20/40 and 20/400 on a standard eye chart
- Your other eye has better vision (at least 20/320) or can see well enough
- You haven't had eye injections with anti-VEGF drugs (like Avastin, Eylea, or Lucentis) in the past 3 months
- Your diabetes and blood pressure are reasonably controlled, and you have no active infections or serious heart/lung disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.
This study tests an oral medication that may reduce swelling in the retina caused by diabetes. If you have diabetic macular edema affecting your central vision, this trial could help you preserve or improve your sight.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.